January 24, 2022
Xiromed LLC Launches Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL)

Florham Park, NJ, January 24, 2022

Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the launch of Sodium Nitroprusside Injection, 50 mg/2 mL (25 mg/mL), generic to Nitropress®.

Xiromed CEO, Narasimhan Mani commented, “The launch of Sodium Nitroprusside Injection is Xiromed’s latest offering from our pipeline of injectable products and demonstrates our commitment to providing value to our institutional customers.”

Annual market sales for Nitropress® and its generics for the twelve month period ending November, 2021 were $3.7 million, according to IQVIA™.   

              Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain.  Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market.  In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products.  Learn more at http://www.xiromed.com/usa/